Related Experiment Videos
Phenotypic differences between Drosophila Alzheimer's disease models expressing human Aβ42 in the developing eye and
Youngjae Jeon1, Soojin Lee1, Myoungchul Shin1
1Department of Biological Sciences, Konkuk University, Seoul, Republic of Korea.
Abstract:
Drosophila melanogaster expressing amyloid-β42 (Aβ42) transgenes have been used as models to study Alzheimer's disease. Various Aβ42 transgenes with different structures induce different phenotypes, which make it difficult to compare data among studies which use different transgenic lines. In this study, we compared the phenotypes of four frequently used Aβ42 transgenic lines, UAS-Aβ42 , UAS-Aβ42 , UAS-Aβ42 , and UAS-Aβ42 . Among the four transgenic lines, only UAS-Aβ42 has two copies of the upstream activation sequence-amyloid-β42 (UAS-Aβ42) transgene, while remaining three have one copy. UAS-Aβ42 has the 3' untranslated region of Drosophila α-tubulin, while the others have that of SV40. UAS-Aβ42 and UAS-Aβ42 have the rat pre-proenkephalin signal peptide, while UAS-Aβ42 and UAS-Aβ42 have that of the fly argos protein. When the transgenes were expressed ectopically in the developing eyes of the flies, UAS-Aβ42 transgene resulted in a strongly reduced and rough eye phenotype, while UAS-Aβ42 only showed a strong rough eye phenotype; UAS-Aβ42 and UAS-Aβ42 had mild rough eyes. The levels of cell death and reactive oxygen species (ROS) in the eye imaginal discs were consistently the highest in UAS-Aβ42 , followed by UAS-Aβ42 , UAS-Aβ42 , and UAS-Aβ42 . Surprisingly, the reduction in survival during the development of these lines did not correlate with cell death or ROS levels. The flies which expressed UAS-Aβ42 or UAS-Aβ42 experienced greatly reduced survival rates, although low levels of ROS or cell death were detected. Collectively, our results demonstrated that different Drosophila AD models show different phenotypic severity, and suggested that different transgenes may have different modes of cytotoxicity. Abbreviations: Aβ42: amyloid-β42; AD: Alzheimer's disease; UAS: upstream activation sequence.